原发性纵隔大B细胞淋巴瘤采用R-CHOP治疗的结局:PET适应策略的影响
本研究纳入159例接受治愈性利妥昔单抗化疗的原发性纵隔大B细胞淋巴瘤患者,94%接受R-CHOP方案。2005年起采用治疗结束PET指导放疗,PET阳性者接受放疗。全队列5年TTP为80%,OS为89%,各治疗时代相似。PET适应策略使多数患者避免放疗。
要点
- 全队列5年TTP为80%,5年OS为89%,各治疗时代相似。
- 113例治疗结束PET扫描中63%阴性、37%阳性,5年TTP分别为90%和71%。
- Deauville评分D5较D4的5年TTP更差(33% vs 87%,P = .0002)。
核心结论
- R-CHOP治疗的PMBCL结局良好,PET适应策略使多数患者减少放疗。
- 小部分患者为难治性疾病,可能受益于替代治疗。
研究设计与样本
- 研究纳入159例年龄≥18岁、接受治愈性利妥昔单抗化疗的PMBCL患者。
- 2005年前为RT时代,推荐R-CHOP+RT;2005年起为PET时代,仅PET阳性者接受RT。
主要发现
- 94%患者接受R-CHOP,44%接受RT(RT时代78%,PET时代28%)。
- 全队列5年TTP为80%,5年OS为89%,各治疗时代相似。
- 10%患者为难治性疾病。
- 113例治疗结束PET扫描中63%阴性、37%阳性,5年TTP分别为90% vs 71%,5年OS分别为97% vs 88%。
- 103例Deauville评分PET中,D1-D3或DX的5年TTP为91%;D5 vs D4的5年TTP为33% vs 87%(P = .0002)。
关键数值与推荐
- PET阴性(D1-D3、DX)5年TTP为91%。
- D5 vs D4的5年TTP为33% vs 87%(P = .0002)。
临床怎么用
- 采用治疗结束PET适应策略可减少多数PMBCL患者的放疗。
- 小部分难治性患者可能受益于替代治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cure rates for primary mediastinal large B-cell lymphoma (PMBCL) have improved with the integration of rituximab. However, the type of primary therapy and role of radiotherapy (RT) remains ill-defined. Herein, we evaluated the outcome of PMBCL primarily treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and the impact of an end-of-treatment (EOT) 18F-fluorodeoxyglucose positron emission tomography (PET) scan to guide consolidative RT. Patients ≥18 years of age with PMBCL treated with curative intent rituximab-chemotherapy were identified. Prior to 2005, patients were recommended to receive R-CHOP + RT (RT era). Beginning in 2005, EOT PET was used to guide RT and only those with a PET-positive scan received RT (PET era). In total, 159 patients were identified, 94% were treated with R-CHOP and 44% received RT (78% in RT era, 28% in PET era). The 5-year time to progression (TTP) and overall survival (OS) for the entire cohort were 80% and 89%, respectively, similar across treatment eras. Overall, 10% had refractory disease. In total, 113 patients had an EOT PET scan: 63% negative and 37% positive with a 5-year TTP of 90% vs 71% and 5-year OS of 97% vs 88%, respectively. For those with Deauville (D)-scored PET scans (n = 103), the 5-year TTP for PET-negative cases by Deauville criteria (D1-D3, DX) was 91%, with inferior outcomes for D5 vs D4 (5-year TTP 33% vs 87%, P = .0002). Outcomes for PMBCL treated with RCHOP are favorable and use of a PET-adapted approach reduces RT in the majority of patients. A small proportion have refractory disease and may benefit from an alternate treatment.
引用
- Hayden AR, Tonseth P, Lee DG, et al. Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. Blood. 2020. PMID: 32603413. doi:10.1182/blood.2019004296
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。